Related Experiment Video
Updated: Aug 5, 2026

Biventricular Assessment of Cardiac Function and Pressure-Volume Loops by Closed-Chest Catheterization in Mice
Published on: June 15, 2020
Blood pressure, left ventricular hypertrophy and long-term prognosis in hemodialysis patients
J M Lopez-Gomez1, E Verde, R Perez-Garcia
1Department of Nephrology, Hospital General Universitario Gregorio Marañón, Madrid, Spain. juanmlopez@senefro.org
Insights
Hypertension is common in hemodialysis patients and linked to cardiovascular events. Strict blood pressure control below 150/90 mm Hg and managing factors like left ventricular hypertrophy are crucial for better outcomes.
Area of Science:
- Nephrology
- Cardiology
- Internal Medicine
Background:
- Cardiovascular events are the leading cause of death in hemodialysis patients.
- Hypertension is prevalent in this population but its impact on mortality is debated.
- Left ventricular hypertrophy (LVH) is a significant predictor of mortality in dialysis patients.
Purpose of the Study:
- To investigate the role of hypertension in cardiovascular mortality among hemodialysis patients.
- To explore the relationship between hypertension, LVH, and other risk factors.
- To suggest optimal blood pressure targets and management strategies.
Main Methods:
- Review of epidemiological studies on hypertension and mortality in hemodialysis.
- Analysis of factors contributing to LVH in chronic renal failure.
- Discussion of current evidence regarding blood pressure goals.
Main Results:
- Discrepancies in studies may stem from inconsistent hypertension definitions and interactions with factors like malnutrition and LVH.
- Predialysis blood pressure below 150/90 mm Hg is suggested to prevent complications.
- Hypertension is a primary driver of LVH, alongside anemia, volume overload, and malnutrition.
Conclusions:
- Strict blood pressure control is essential for hemodialysis patients.
- Managing factors contributing to LVH, such as anemia and malnutrition, is critical.
- Angiotensin-converting enzyme (ACE) inhibitors are recommended for blood pressure management.
Abstract:
Cardiovascular events are the main cause of death in patients with chronic renal failure who are treated with hemodialysis. Hypertension is frequent among dialysis patients and may be a major cause of mortality, although epidemiological studies are controversial in this regard. This disparity in results may be the consequence of an inadequate definition of hypertension in dialysis patients as well as the interaction with hypertension with other risk factors such as malnutrition or left ventricular hypertrophy (LVH), which are strong predictors of death. Although the goal of blood pressure in dialysis has not been established yet, it seems that predialysis blood pressure levels lower than 150/90 mm Hg must be achieved for patients to avoid complications. LVH is very frequent among dialysis patients and starts early in the progression of chronic renal failure. Hypertension is the main cause for its development, but other potentially reversible factors such as anemia, volume overload, secondary hyperparathyroidism, dose of dialysis or malnutrition may also be implicated. Hence, an adequate management of patients on hemodialysis must include the strict control of blood pressure, preferably with angiotensin converting enzyme (ACE) inhibitors, together with those early measures in order to avoid the development of the other causes of LVH or to treat them when they already exist.
Related Concept Videos
Pathophysiology of Heart Failure
Mitral Regurgitation I: Introduction
Heart Failure II: Pathophysiology
Heart Failure VI: Adjunct Therapies
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hemodialysis II: Procedure and Complications

